ArticleCureus2025
Fibrolamellar Hepatocellular Carcinoma: A Case Report of 25-Year Postoperative Survival.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare hepatocellular carcinoma (HCC) variant. We report a 46-year-old patient with FLHCC who has achieved 25 years of postoperative survival, the longest reported to date. The patient underwent a right hepatic lobectomy, lymph node resection, and peritoneal dissemination removal. Over the years, he underwent seven additional surgeries for recurrences in various sites, including the intraperitoneal area, left lung, mediastinal lymph nodes, spleen, and transverse colon. To date, he has undergone a total of 14 surgeries, including eight for recurrences. FLHCC frequently recurs postoperatively despite its indolent nature. The patient's cancer antigen 125 (CA125) levels correlated well with recurrence and treatment efficacy, confirming it to be a reliable tumor marker. Currently, the patient is undergoing radiation therapy for recurrence in the mediastinal lymph nodes. This case highlights the potential for long-term survival with aggressive surgical intervention and vigilant follow-up, emphasizing the importance of surgical resection and monitoring in FLHCC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.